Cognition Therapeutics schedules Type C meeting with FDA on CT1812 Phase 3 endpoints for DLB
Cognition Therapeutics has scheduled a Type C meeting with the FDA's Division of Neurology for October 20th to align on primary and secondary endpoints for a Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB).
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
Cognition Therapeutics announced a Type C meeting with the FDA scheduled for October 20th with the Division of Neurology. The meeting agenda is to define and align on endpoints for the Phase 3 trial of CT1812 in DLB.
Why it matters
Type C meetings are pre-trial alignment sessions where sponsors and regulators negotiate trial design, endpoints, and success criteria. Endpoint agreement is a critical gating step: misalignment post-Phase 3 can invalidate trial results or force costly redesigns. Successful alignment reduces regulatory risk and increases probability of approvability, directly affecting clinical-stage valuation and future cash flow expectations.
Market transmission
Positive endpoint alignment → reduced Phase 3 execution risk → lower discount rate applied to future approval probability → higher equity valuation. Conversely, endpoint disagreement or delays → extended timelines → increased cash burn and dilution risk. DLB is an underserved neurodegenerative indication; successful Phase 3 could support premium pricing and market exclusivity.
What to watch
Outcome of October 20th meeting (endpoint agreement vs. requests for additional data/redesign); any subsequent press release confirming FDA alignment; Phase 3 enrollment timeline and patient population definition; competitive pipeline activity in DLB (e.g., other anti-amyloid or tau programs).
Source:GlobeNewswire US
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.